LGNXZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 63,693,000 | 55,596,000 | 8,591,000 | 48,508,000 | 2,185,875,000 | 1,006,702,000 | 1,218,359,000 |
| Mar 2026 | 51,722,000 | 43,625,000 | 17,368,000 | -13,345,000 | 1,532,105,000 | 115,077,000 | 534,783,000 |
| Sep 2025 | 115,461,000 | 107,364,000 | 54,931,000 | 117,273,000 | 1,476,772,000 | 139,376,000 | 526,601,000 |
| Jun 2025 | 47,627,000 | 39,369,000 | 8,444,000 | 4,847,000 | 948,604,000 | 67,669,000 | 120,075,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$306,899,008
EBITDA
$117,036,000
Free Cash Flow
$139,748,880
Enterprise Value
—
Total Cash
$447,395,008
Total Debt
$1,128,216,960
Shares Out
—
Trailing EPS
—
Book Value
$48.57
ROE
5.4%
ROA
2.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,087,000 | 41,002,000 | 124,453,000 | 1,560,637,000 | 543,425,000 | 1,017,212,000 | — |
| Dec 2024 | 167,133,000 | -22,606,000 | -4,032,000 | 941,774,000 | 111,335,000 | 830,439,000 | — |
| Dec 2023 | 131,314,000 | 11,942,000 | 52,154,000 | 787,216,000 | 86,303,000 | 700,913,000 | — |
| Dec 2022 | 196,245,000 | 3,037,000 | -33,361,000 | 762,668,000 | 165,183,000 | 597,485,000 | — |
| Dec 2021 | 277,133,000 | 78,895,000 | 57,138,000 | 1,297,590,000 | 476,431,000 | 821,159,000 | — |
| Dec 2020 | 186,419,000 | 25,845,000 | -2,985,000 | 1,362,285,000 | 652,760,000 | 709,525,000 | — |
| Dec 2019 | 120,282,000 | 807,076,000 | 629,302,000 | 1,494,915,000 | 727,683,000 | 767,232,000 | — |
| Dec 2018 | 251,453,000 | 163,727,000 | 143,321,000 | 1,260,803,000 | 699,889,000 | 560,914,000 | — |
| Dec 2017 | 141,102,000 | 68,076,000 | 12,556,000 | 671,021,000 | 252,374,000 | 399,788,000 | — |
| Dec 2016 | 108,973,000 | 43,885,000 | -1,636,000 | 601,585,000 | 230,732,000 | 341,290,000 | — |
TTM Snapshot
Revenues TTM
$290,542,000
NetIncome TTM
$197,220,000
OpCashFlow TTM
—
Assets (Latest)
$2,185,875,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Oracle upgraded, Reddit downgraded: Wall Street's top analyst calls
2026-11-02 14:55 · Yahoo
Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
2026-10-30 17:12 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
2026-10-30 17:09 · Yahoo
Ligand (LGND) Q3 2026 Earnings Call Transcript
2026-10-30 14:46 · Yahoo
Ligand Pharmaceuticals Incorporated Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
2026-10-29 19:14 · Yahoo
Ligand: Q3 Earnings Snapshot
2026-10-29 11:20 · Yahoo
Ligand Reports Third Quarter 2026 Financial Results
2026-10-29 11:00 · Yahoo
Ligand to Participate in November Investor Conferences
2026-10-27 20:01 · Yahoo
Ligand to Host Investor Day on December 8, 2026
2026-10-22 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.